Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593467 | 0.94 | PSMB8 (0.30) | ALDH1A1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL5223027 | 0.91 | PSMB8 (0.31) | PSMB8PSMB5 | |
| SCHEMBL27701450 | 0.85 | PSMB8 (0.30) | PSMB8PSMB5 | |
| SCHEMBL14644916 | 0.83 | PSMB8 (0.33) | PSMB8PSMB5 | |
| SCHEMBL2589620 | 0.83 | PSMB8 (0.34) | PSMB8PSMB5 | |
| SCHEMBL43576 | 0.81 | PSMB8 (0.35) | MAPK1SMN1; SMN2PSMB8PSMB5 | |
| SCHEMBL15760606 | 0.80 | PSMB8 (0.31) | PSMB8PSMB5 | |
| SCHEMBL141048 | 0.80 | ADRA2A (0.36) | ALDH1A1SMN1; SMN2PSMB8PSMB5 | |
| Ethylene Glycol SCHEMBL999673 | 0.79 | PSMB8 (0.36) | PSMB8PSMB5 | |
| SCHEMBL20713864 | 0.79 | GSTP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | THERAGENICS CORPORATION | 2019-08-29 | — | — | US | claimed |
| US-10189773-B2 | In-vivo gelling pharmaceutical pre-formulation | MEDICUS BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | claimed |
| EP-2846847-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | Medicus Biosciences LLC (US) | 2015-03-18 | — | — | EP | claimed |
| WO-2013170195-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES, LLC (US) | 2013-11-14 | — | — | WO | claimed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | claimed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | claimed |
| EP-1824414-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MicroVention, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| US-7201918-B2 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2007-04-10 | — | — | US | claimed |
| WO-2006055690-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MICROVENTION, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20060105014-A1 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2006-05-18 | — | — | US | claimed |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | AQUARIAN CREDIT FUNDING LLC | 2023-07-13 | — | — | US | disclosed |
| EP-2968680-B1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | C P MEDICAL CORP (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | AQUARIAN CREDIT FUNDING LLC | 2023-03-07 | — | — | US | disclosed |
| US-20210322785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | THERAGENICS CORPORATION | 2021-10-21 | — | — | US | disclosed |
| EP-3893785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | C.P. Medical Corporation (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-1824414-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MicroVention, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7201918-B2 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| WO-2006055690-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MICROVENTION, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060105014-A1 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189773-B2 | In-vivo gelling pharmaceutical pre-formulation | FURIN, ARFGAP1, MGST1 | ALDH1A1 84/4885TP53 1611/4885CYP3A4 339/4885 |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | ALDH1A2, RB1, UACA | ALDH1A1 297/4885TP53 2618/4885CYP3A4 4794/4885 |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | ALDH1A2, RB1, UACA | ALDH1A1 297/4885TP53 2618/4885CYP3A4 4794/4885 |
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | ALDH1A1 113/4885TP53 1767/4885CYP3A4 454/4885 |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | ALDH1A1 84/4885TP53 1611/4885CYP3A4 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.